Standard BioTools Inc. (LAB) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $0.93 (+0.33%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 4, 2024 | Matthew Stanton | Jefferies | $3.25 | +248.8% |
Top Analysts Covering LAB
LAB vs Sector & Market
| Metric | LAB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +248.8% | +1150.0% | +14.9% |
| P/E Ratio | -4.74 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $81M | $82M | $82M | 2 |
| 2027-03-31 | $18M | $19M | $19M | 1 |
| 2027-06-30 | $21M | $21M | $22M | 1 |
| 2027-09-30 | $20M | $20M | $20M | 1 |
| 2027-12-31 | $23M | $23M | $24M | 1 |
| 2028-03-31 | $20M | $20M | $20M | 1 |
| 2028-06-30 | $22M | $22M | $23M | 1 |
| 2028-09-30 | $21M | $22M | $22M | 1 |
| 2028-12-31 | $25M | $26M | $26M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.13 | $-0.13 | $-0.12 | 1 |
| 2027-03-31 | $-0.03 | $-0.03 | $-0.03 | 1 |
| 2027-06-30 | $-0.03 | $-0.03 | $-0.02 | 1 |
| 2027-09-30 | $-0.03 | $-0.03 | $-0.02 | 1 |
| 2027-12-31 | $-0.02 | $-0.02 | $-0.02 | 1 |
| 2028-03-31 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-06-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-09-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-12-31 | $-0.01 | $-0.01 | $-0.01 | 1 |
Frequently Asked Questions
What is the analyst consensus for LAB?
The consensus among 1 analysts covering Standard BioTools Inc. (LAB) is Hold with an average price target of $3.25.
What is the highest price target for LAB?
The highest price target for LAB is $3.25, set by Matthew Stanton at Jefferies on 2024-04-04.
What is the lowest price target for LAB?
The lowest price target for LAB is $3.25, set by Matthew Stanton at Jefferies on 2024-04-04.
How many analysts cover LAB?
1 analysts have issued ratings for Standard BioTools Inc. in the past 12 months.
Is LAB a buy or sell right now?
Based on 1 analyst ratings, LAB has a consensus rating of Hold (3.00/5) with a +248.8% upside to the consensus target of $3.25.
What are the earnings estimates for LAB?
Analysts estimate LAB will report EPS of $-0.13 for the period ending 2026-12-31, with revenue estimated at $82M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.